Difference between revisions of "Colorectal cancer, BRAF-mutated"
Jump to navigation
Jump to search
m |
Ryannguyen (talk | contribs) |
||
| Line 47: | Line 47: | ||
|style="background-color:#1a9851"|Phase III (E) | |style="background-color:#1a9851"|Phase III (E) | ||
|1. Irinotecan & Cetuximab <br> 2. FOLFIRI & Cetuximab | |1. Irinotecan & Cetuximab <br> 2. FOLFIRI & Cetuximab | ||
| − | | style="background-color:# | + | | style="background-color:#1a9851" |Superior OS |
|- | |- | ||
|} | |} | ||
| Line 77: | Line 77: | ||
|style="background-color:#1a9851"|Randomized Phase II (E) | |style="background-color:#1a9851"|Randomized Phase II (E) | ||
| Irinotecan & Cetuximab | | Irinotecan & Cetuximab | ||
| − | | style="background-color:# | + | | style="background-color:#1a9851" |Superior PFS |
|- | |- | ||
|} | |} | ||
| Line 89: | Line 89: | ||
===References=== | ===References=== | ||
# '''Abstract:''' Kopetz S, McDonough S, Morris V, Lenz HJ, Magliocco A, Atreya C, Diaz L, Allegra C, Lieu C, Wang S, Eckhardt SG, Semrad T, Kaberle K, Guthrie K, Hochster H. Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). Journal of Clinical Oncology 35, no. 4_suppl (February 01, 2017) 520-520. Published online March 21, 2017. [https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.520 link to abstract] | # '''Abstract:''' Kopetz S, McDonough S, Morris V, Lenz HJ, Magliocco A, Atreya C, Diaz L, Allegra C, Lieu C, Wang S, Eckhardt SG, Semrad T, Kaberle K, Guthrie K, Hochster H. Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). Journal of Clinical Oncology 35, no. 4_suppl (February 01, 2017) 520-520. Published online March 21, 2017. [https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.4_suppl.520 link to abstract] | ||
| + | |||
| + | ==Dabrafenib, Trametinib, Panitumumab{{#subobject:aab14c|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | ===Regimen {{#subobject:98buya|Variant=1}}=== | ||
| + | {| class="wikitable" style="width: 75%; text-align:center;" | ||
| + | !style="width: 33%"|Study | ||
| + | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]] | ||
| + | |- | ||
| + | |[https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103 Atreya CE et al. 2017] | ||
| + | |style="background-color:#91cf61"|Phase I/II (E) | ||
| + | |style="background-color:#6e016b; color:white| ORR: 26% | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | *[[Dabrafenib (Tafinlar)]] 150mg PO twice per day | ||
| + | *[[Trametinib (Mekinist)]] 2mg PO once per day | ||
| + | *[[Panitumumab (Vectibix)]] 6mg/kg IV on day 1 | ||
| + | |||
| + | '''14-day cycles''' | ||
| + | |||
| + | ===References=== | ||
| + | # '''Abstract:''' Chloe EA, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, McRee AJ, O'Dwyer PJ, Muro K, Tabernero J, Van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, Wu Y, Orford KW, and Corcoran RB. Journal of Clinical Oncology 2015 33:15_suppl, 103-103. Published online January 31, 2017. [https://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.103 link to abstract] | ||
[[Category:Colon cancer regimens]] | [[Category:Colon cancer regimens]] | ||
[[Category:Biomarker-specific pages]] | [[Category:Biomarker-specific pages]] | ||
[[Category:Colorectal cancers]] | [[Category:Colorectal cancers]] | ||
Revision as of 22:36, 6 November 2019
| Section editor | |
|---|---|
 |
Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL |
Note: the page has regimens specific to BRAF-mutated colon cancer.
- See the main colon cancer page for general regimens.
4 regimens on this page
5 variants on this page
|
Guidelines
ESMO
- 2016: Van Cutsem et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. PubMed
Older
- 2013: Labianca et al. Early Colon Cancer: ESMO Clinical Practice Guidelines PubMed
- 2013: Balmaña et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. PubMed
Japanese Society for Cancer of the Colon and Rectum
- 2016: Watanabe et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer PubMed
NCCN
SIOG
- 2014: Papamichael et al. Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
Advanced or metastatic disease, second or third-line therapy
Binimetinib, Encorafenib, Cetuximab
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Kopetz et al. 2019 (BEACON) | Phase III (E) | 1. Irinotecan & Cetuximab 2. FOLFIRI & Cetuximab |
Superior OS |
Chemotherapy
- Binimetinib (Mektovi) 45 mg PO twice per day
- Encorafenib (Braftovi) 300 mg PO once per day
- Cetuximab (Erbitux) as follows:
- Cycle 1: 400 mg/m2 IV over 120 minutes once on day 1, then 250 mg/m2 IV over 60 minutes once per day on days 8, 15, 22
- Cycle 2 onwards: 250 mg/m2 IV over 60 minutes once per day on days 1, 8, 15, 22
28-day cycles
References
- BEACON: Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer. N Engl J Med. 2019 Oct 24;381(17):1632-1643. Epub 2019 Sep 30. link to original article contains verified protocol PubMed
Irinotecan, Vemurafenib, Cetuximab
| back to top |
Regimen
| Study | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|
| Kopetz et al. 2017 (SWOG 1406) | Randomized Phase II (E) | Irinotecan & Cetuximab | Superior PFS |
Chemotherapy
- Irinotecan (Camptosar) 180 mg/m2 IV once on day 1
- Vemurafenib (Zelboraf) 960 mg PO twice per day
- Cetuximab (Erbitux) 500 mg/m2 IV once on day 1
14-day cycles
References
- Abstract: Kopetz S, McDonough S, Morris V, Lenz HJ, Magliocco A, Atreya C, Diaz L, Allegra C, Lieu C, Wang S, Eckhardt SG, Semrad T, Kaberle K, Guthrie K, Hochster H. Randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG1406). Journal of Clinical Oncology 35, no. 4_suppl (February 01, 2017) 520-520. Published online March 21, 2017. link to abstract
Dabrafenib, Trametinib, Panitumumab
| back to top |
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Atreya CE et al. 2017 | Phase I/II (E) | ORR: 26% |
Chemotherapy
- Dabrafenib (Tafinlar) 150mg PO twice per day
- Trametinib (Mekinist) 2mg PO once per day
- Panitumumab (Vectibix) 6mg/kg IV on day 1
14-day cycles
References
- Abstract: Chloe EA, Van Cutsem E, Bendell JC, Andre T, Schellens JHM, Gordon MS, McRee AJ, O'Dwyer PJ, Muro K, Tabernero J, Van Geel R, Sidhu R, Greger JG, Rangwala FA, Motwani M, Wu Y, Orford KW, and Corcoran RB. Journal of Clinical Oncology 2015 33:15_suppl, 103-103. Published online January 31, 2017. link to abstract